Center of Infectious Diseases, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Wuhou District, Chengdu, Sichuan Province, China.
Center of Infectious Diseases, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Wuhou District, Chengdu, Sichuan Province, China.
Biomed Pharmacother. 2019 Feb;110:641-645. doi: 10.1016/j.biopha.2018.12.004. Epub 2018 Dec 10.
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL has recently been suggested as a potential therapeutic target in hepatocellular carcinoma (HCC) because it promotes apoptosis in cancer cells. Furthermore, studies on the role of TRAIL in liver injury have reported that TRAIL plays an essential role in viral hepatitis, fatty liver diseases, etc. However, several contradictory and confounding effects of TRAIL in these liver diseases have not been fully elucidated or placed into perspective. Hence, this review summarizes recent progress in studies on TRAIL, including its role in apoptotic signaling, potential therapeutic applications of TRAIL in HCC, hepatitis virus infection, and liver fibrosis and cirrhosis.
肿瘤坏死因子相关凋亡诱导配体（TRAIL）是一种潜在的抗肿瘤蛋白，其能够选择性地消除各种类型的肿瘤细胞，而对正常细胞和组织没有毒性作用。TRAIL 最近被提议作为肝细胞癌（HCC）的潜在治疗靶点，因为它能促进癌细胞凋亡。此外，关于 TRAIL 在肝损伤中的作用的研究表明，TRAIL 在病毒性肝炎、脂肪肝等疾病中发挥着重要作用。然而，TRAIL 在这些肝脏疾病中的一些矛盾和混淆的作用尚未得到充分阐明或理解。因此，本综述总结了 TRAIL 的研究进展，包括其在凋亡信号中的作用、TRAIL 在 HCC、肝炎病毒感染以及肝纤维化和肝硬化中的潜在治疗应用。
